Key PointsQuestion Does the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increase the risk of developing neovascular age-related macular degeneration (nAMD) in patients with diabetes?Findings In this population-based cohort study that included 139 002 matched patients, a substantially higher estimated risk of developing nAMD was observed among patients exposed to GLP-1 RAs compared with unexposed patients.Meaning More than twice as many patients with diabetes exposed to GLP-1 RAs...